Skip to content
phase 2GI & Metabolic

Motilin

Also known as: MLN, Motilin Peptide

Motilin is a 22-amino-acid peptide hormone produced by enteroendocrine Mo-cells of the duodenum and jejunum. It is the primary regulator of the migrating motor complex (MMC) — the cyclic pattern of interdigestive GI motility that occurs every 90–120 minutes during fasting to sweep residual food, bacteria, and debris through the small intestine. Motilin receptor (MLNR) agonists, including the macrolide antibiotic erythromycin, are investigated as prokinetic agents for gastroparesis and other motility disorders.

3 cited references·5 researched benefits

Quick Answer

Motilin is a 22-amino-acid gut hormone that controls the migrating motor complex (MMC) — the cyclical "housekeeper" contractions that sweep the small intestine clean between meals every 90–120 minutes. Released from duodenal Mo-cells during fasting, motilin triggers phase III MMC contractions. Erythromycin acts as a motilin receptor agonist, which is why it is used off-label as a prokinetic for gastroparesis. Selective motilin agonists are in development for GI motility disorders.

Key Facts

Mechanism
Motilin is cyclically released from Mo-cells during the fasting state, with plasma levels peaking every 90–120 minutes in synchrony with phase III of the MMC. It binds the motilin receptor (MLNR/GPR38), a GPCR expressed on smooth muscle cells of the gastric antrum and duodenum, as well as enteric neurons. Receptor activation triggers smooth muscle contraction through Gq-PLC-IP₃-mediated calcium release, initiating the powerful phase III MMC contractions that propagate aborally through the small intestine. This "interdigestive housekeeper" function prevents bacterial overgrowth (SIBO) and clears undigested material. Eating abolishes the MMC by suppressing motilin release (postprandial motility patterns are controlled by other mechanisms). Erythromycin and related macrolide antibiotics bind the motilin receptor as agonists, explaining their prokinetic effects and the side effect of GI cramping.
Research Status
phase 2
Half-Life
~4–5 minutes
Molecular Formula
C₁₁₄H₁₇₅N₃₃O₂₈S
Primary Use
GI & Metabolic
Table of Contents

Benefits

  • Migrating motor complex regulation — essential physiological role in initiating MMC phase III contractions for intestinal housekeepingstrong
  • Gastroparesis treatment target — motilin receptor agonism accelerates gastric emptying in diabetic and idiopathic gastroparesismoderate
  • SIBO prevention mechanism — MMC-driven intestinal clearance prevents small intestinal bacterial overgrowth; impaired motilin signaling is associated with SIBOmoderate
  • Postoperative ileus target — motilin agonists are investigated for recovery of GI motility after abdominal surgerypreliminary
  • Functional dyspepsia research — altered motilin cycling is observed in functional dyspepsia, suggesting therapeutic potentialpreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous (research/diagnostic)0.5–2 mcg/kgSingle dose or short-term infusionUsed in research settings to trigger MMC phase III contractions. Not commercially available as a therapeutic product. Rapid tachyphylaxis limits repeated dosing.
Oral (erythromycin as motilin agonist — off-label)50–250 mg3× daily, 30 minutes before mealsLow-dose erythromycin (50–100 mg) is used off-label as a prokinetic for gastroparesis. Antibiotic activity is minimal at these doses. Efficacy wanes after 4–6 weeks due to tachyphylaxis. Used as bridge therapy while establishing other treatments.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Abdominal cramping — strong smooth muscle contractions can cause painful cramping, especially at supratherapeutic dosescommon
  • Nausea — excessive gastric contractions can provoke nauseacommon
  • Diarrhea — accelerated intestinal transit from enhanced motilitycommon
  • Tachyphylaxis — rapid desensitization of the motilin receptor limits sustained therapeutic use; a major challenge for drug developmentcommon
  • QT prolongation risk — macrolide motilin agonists (erythromycin) carry cardiac risk; selective motilin agonists aim to avoid thisserious

Frequently Asked Questions

What is the migrating motor complex and why is motilin important for it?
The migrating motor complex (MMC) is a cyclic pattern of electromechanical activity in the GI tract that occurs during fasting (between meals). It has three phases: phase I (quiescence), phase II (irregular contractions), and phase III (powerful, sweeping contractions). Motilin triggers the phase III contractions — intense peristaltic waves that propagate from the stomach through the small intestine every 90–120 minutes, clearing residual food, bacteria, dead cells, and mucus. This "housekeeper" function prevents bacterial overgrowth. When motilin signaling is disrupted (e.g., in diabetes or after vagotomy), SIBO and motility disorders can develop.
Why is erythromycin used as a prokinetic for gastroparesis?
Erythromycin, a macrolide antibiotic, was discovered to bind and activate the motilin receptor in the 1980s. At subtherapeutic antibiotic doses (50–250 mg), it acts as a motilin agonist, triggering gastric contractions that accelerate emptying. It is the most potent available prokinetic for gastroparesis, superior to metoclopramide for gastric emptying acceleration. However, its use is limited by tachyphylaxis (receptor desensitization within 4–6 weeks), QT prolongation risk, antibiotic resistance concerns, and drug interactions via CYP3A4 inhibition.
What is motilin receptor tachyphylaxis and why does it matter?
Tachyphylaxis is the rapid loss of drug response after repeated dosing. Motilin receptor agonists consistently produce tachyphylaxis within days to weeks — the receptor desensitizes and internalizes, reducing the prokinetic response. This has been the single biggest barrier to developing motilin-based drugs for gastroparesis. Erythromycin's prokinetic effect typically wanes by 4–6 weeks of continuous use. Research strategies to overcome this include intermittent dosing schedules (drug holidays), partial agonists with reduced desensitization potential, and biased agonists that activate beneficial signaling pathways without triggering receptor internalization.
How does impaired motilin signaling contribute to SIBO?
The MMC phase III contractions triggered by motilin serve as the primary defense against small intestinal bacterial overgrowth (SIBO). These sweeping contractions physically clear bacteria from the small intestine, maintaining relatively low bacterial counts (<10⁴ CFU/mL). Conditions that impair motilin release or MMC function — including diabetes, scleroderma, hypothyroidism, opioid use, and post-surgical states — are strongly associated with SIBO. Prokinetic therapy targeting motilin receptors can restore MMC cycling and is sometimes used adjunctively in SIBO management alongside antibiotics.

References

  1. 1
    Motilin and the migrating motor complex: role of interdigestive motility in health and disease(1991)PubMed ↗
  2. 2
    Motilin receptor agonists for treatment of GI motility disorders: past, present, and future(2010)PubMed ↗
  3. 3
    Erythromycin as a prokinetic agent: a systematic review of its efficacy in gastroparesis(2009)PubMed ↗

Latest Research

Last updated: 2026-02-19